Direct from Yineng Pharma (MedGence) cGMP facilities: turn-key botanical active identification, purity enrichment, toxicology assaying, and multicenter clinical evidence generation.
Bridging classical pharmacognosy and 21st-century bio-engineering through standardized molecular quantification, multi-target synergy isolation, and traceable industrialization.
The global phyto-pharmaceutical and functional nutrition industries face an existential challenge: raw herbal material exhibits profound variability based on agro-climatic zones, diurnal rhythms, harvest timing, soil chemistry, and post-harvest drying. Traditional contract manufacturing organizations (CMOs) treat plant materials as generic dry commodities, yielding extracts with wildly fluctuating bioactivity.
At MedGence (Yineng Pharma), our ODM methodology shifts botanical extraction into a precision-engineered science. By combining HPTLC identification, multi-wavelength HPLC assays, GC-MS volatile profiling, and dynamic Q-markers (Quality Markers), we map the entire active matrix—including polyphenols, saponins, triterpenoids, polysaccharides, and alkaloids. We isolate active compounds, eliminate inert ballast, and standardize batch potencies to tight specifications (±1.5% active marker variance), offering uncompromised predictability for global pharmaceutical and nutraceutical innovators.
Navigating cross-border regulatory hurdles requires rigorous analytical documentation. Phytochemicals exported from China to North America, the European Union, and Asia-Pacific must pass stringent toxicity screens, pesticide limits, heavy metal thresholds, residual solvent tests, and microbiological validations.
MedGence operates under fully accredited cGMP, ISO9001, ISO22000, and GLP frameworks. Every pilot and commercial ODM production run is delivered with an exhaustive Certificate of Analysis (CoA) substantiated by validated analytical methods, third-party ring-testing data, and stability studies conducted under ICH conditions (Zone II and Zone IVb). Whether our clients are compiling an Investigational New Drug (IND) Botanical Dossier for the US FDA, registering a Traditional Herbal Medicinal Product (THMPD) in the EU, or securing NPN status under Health Canada, our regulatory dossiers ensure accelerated market clearances.
Combining natural megadiversity, indigenous agro-ecological hubs, continuous-flow extraction automation, and unrivaled cost-to-potency economics.
China houses over 12,000 distinct medicinal plant species spanning sub-arctic, temperate, subtropical, and alpine plateaus. Yineng Pharma leverages direct-contract cultivation in authentic Daodi medicinal zones across Hunan, Yunnan, Sichuan, Shaanxi, and Guizhou.
Our Changsha manufacturing complex integrates automated countercurrent continuous extraction, Supercritical CO2 Fluid Extraction (SFE-CO2), industrial macroporous resin column chromatography, membrane nanofiltration, and low-temperature vacuum freeze-drying.
China's mature bio-manufacturing cluster offers unparalleled raw material consolidation, continuous supply chains, and highly cost-competitive technical labor. By working directly with an integrated CRO/CDMO, clients save up to 45% in development and commercial scaling costs.
Strategic market analysis of regulatory transitions, consumer clean-label demand, AI computational biology, and green extraction mandates.
Computational biology and in silico molecular docking now predict receptor-binding affinities for complex plant polyphenols and alkaloids before clinical testing, reducing R&D screening cycles from years to months.
Modern formulations demand liposomal encapsulation, phytosomes, microemulsions, and cyclodextrin complexes that elevate the oral bioavailability of hydrophobic molecules like curcumin, resveratrol, and berberine by over 800%.
Global pharmaceuticals are embracing botanical multi-component synergy. Complex herbal polyherbal formulations act on redundant metabolic pathways without eliciting the drug-resistance common in single-target synthetic compounds.
Global ESG directives demand zero petro-chemical solvent traces. Hydro-distillation, Deep Eutectic Solvents (NADES), and high-pressure subcritical water extraction are replacing hazardous organic solvents like chloroform and hexane.
From water-soluble functional beverages to target therapeutics, our formulation engineers optimize stability, palatability, and bio-distribution.
Phytochemical fractions formulated for glucose metabolism, AMPK activation, and lipid profile regulation.
Blood-brain barrier (BBB) permeating actives designed to support neurogenesis, cholinergic signaling, and oxidative stress resilience.
Botanical actives designed for topical collagen stimulation, tyrosinase inhibition, and photoprotective anti-senescence.
From single-compound target screening to turn-key finished drug manufacture, Yineng Pharma covers the complete product life cycle.
Eliminating supply disruptions, regulatory audit failures, and adulteration hazards with our multi-layered supply chain governance.
Global enterprise procurement teams require ironclad guarantees against environmental residues. MedGence employs triple-quadrupole ICP-MS and LC-MS/MS testing for every single batch.
Supply agreements require transparent regulatory paper trails to withstand audits from the FDA, EFSA, TGA, or local health authorities.
Procurement directors avoid single-point failure risks. We establish redundant raw herb buffering and dynamic inventory fulfillment contracts.
Comprehensive scientific and operational answers for procurement directors, regulatory heads, and formulation chemists.
Select from our verified clinical, in vivo, chromatographic, and screening workflows to accelerate your botanical product development timeline.